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Abstract
Background—Our recent genome-wide association study identified a novel breast cancer
susceptibility locus at 9q31.2 (rs865686).
Methods—To further investigate the rs865686–breast cancer association, we conducted a
replication study within the Breast Cancer Association Consortium, which comprises 37 case–
control studies (48,394 cases, 50,836 controls).
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Results—This replication study provides additional strong evidence of an inverse association
between rs865686 and breast cancer risk [study-adjusted per G-allele OR, 0.90; 95% confidence
interval (CI), 0.88; 0.91, P = 2.01 × 10–29] among women of European ancestry. There were ethnic
differences in the estimated minor (G)-allele frequency among controls [0.09, 0.30, and 0.38
among, respectively, Asians, Eastern Europeans, and other Europeans; P for heterogeneity (Phet) =
1.3 × 10–143], but no evidence of ethnic differences in per allele OR (Phet = 0.43). rs865686 was
associated with estrogen receptor–positive (ER+) disease (per G-allele OR, 0.89; 95% CI, 0.86–
0.91; P = 3.13 × 10–22) but less strongly, if at all, with ER-negative (ER–) disease (OR, 0.98; 95%
CI, 0.94–1.02; P = 0.26; Phet = 1.16 × 10–6), with no evidence of independent heterogeneity by
progesterone receptor or HER2 status. The strength of the breast cancer association decreased with
increasing age at diagnosis, with case-only analysis showing a trend in the number of copies of the
G allele with increasing age at diagnosis (P for linear trend = 0.0095), but only among women
with ER+ tumors.
Conclusions—This study is the first to show that rs865686 is a susceptibility marker for ER+
breast cancer.
Impact—The findings further support the view that genetic susceptibility varies according to
tumor subtype.
Introduction
Several genome-wide association studies (GWAS) have examined, since 2007, the role of
common genetic variation in breast cancer risk leading to the identification of more than 20
risk loci (1–10). We recently conducted a multi-stage GWAS, involving a total of 11,781
cases and 12,378 controls that identified a novel breast cancer locus at 9q31.2 (rs865686)
with an estimated per G-allele OR of 0.89 [95% confidence interval (CI) 0.85–0.92, P = 1.75
× 10–10 (11; Fig. 1)]. Although this result is statistically significant by the usual criteria,
rs865686 lies over 600 kb from the nearest gene and is not in linkage disequilibrium with
any genomic elements that suggest a possible causal mechanism. Statistical replication of
this association is therefore important to establish this region as a risk locus for breast
cancer. To provide a more precise estimate of the magnitude of the rs865686 association
with breast cancer risk, we conducted a replication study within the Breast Cancer
Association Consortium (BCAC), a large international consortium comprising more than
95,000 breast cancer cases and controls, which has been used to confirm most other GWAS-
identified breast cancer susceptibility loci (e.g., refs. 12–14). This large case–control series
also provided an opportunity to investigate whether the strength of the SNP–breast cancer
association varies by ethnicity, age at diagnosis, or tumor subtype.
Materials and Methods
Study subjects
Thirty-seven BCAC case–control studies contributed to this analysis. A brief description of
the participating studies is given in Supplementary Table S1. The large majority of women
(98%) were of self-reported European descent; those who participated in studies conducted
in Eastern European countries (HMBCS and HUBCS) and those in OFBCR, who self-
reported themselves as being Eastern European, were further classified as Eastern
Europeans. In all, 2% were of self-reported Asian ethnicity; the latter included all the
participants in the only study (ACP) conducted in Asia as well as Asians who participated in
other studies (restricted to studies with at least 20 Asians). Women of other self-reported
ethnicities were excluded because of small numbers. Data on morphology (invasive vs. in
situ) and receptor status [estrogen receptor (ER), progesterone receptor (PR), and HER2],
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obtained mainly from clinical notes, were available for certain subsets of cases
(Supplementary Table S2).
Each study was approved by the relevant Institutional Review Boards/Ethics Committees.
Written informed consent was obtained from each subject. Only anon-ymised data were
made available to BCAC.
Genotyping
9q31.2-rs865686 was genotyped by MALDI-TOF MS (Sequenom), TaqMan (Applied
Biosystems) or Fluidigm technologies (Fluidigm) using standard protocols (Supplementary
Table S3). Strict quality control criteria, as implemented by BCAC (15), were applied.
Briefly, the genotyping concordance was verified by including at least 2% of samples in
duplicate and a common set of 93 CEPH DNAs used by the HapMap Consortium
(HAPMAPPT01, Coriell Institute for Medical Research, Cambden, NJ). All samples from
any study with more than 2 discordant genotypes on the CEU plate were excluded. Overall
single nucleotide polymorphism (SNP) call rates were more than 97% for all studies
(Supplementary Table S3). There was no evidence of departure from Hardy–Weinberg
equilibrium (HWE) among controls in any individual participating study (P > 0.01 for all
studies; Supplementary Table S3).
Statistical methods
The SNP association with breast cancer risk was assessed by estimating per-allele ORs with
95% CI. Two European BCAC studies (BBCS and UKBGS) had contributed data to the
original GWAS and were therefore analysed separately as the “discovery” (hypothesis-
generating) set; cases and controls of self-reported European ancestry from the remaining
BCAC studies constituted the independent “replication” set (Fig. 1).
In secondary analyses, data from the discovery and replication sets were combined to
maximize power. There is a possibility of “winner's curse” bias in this approach, which we
assessed by comparing the primary SNP association in the combined data to the unbiased
estimate in the replication set and also to the more accurate unbiased uniformly minimum
variance conditional unbiased estimator (UMVCUE) proposed by Bowden and Dudbridge
(16), which corrects for a “winner's curse” effect in stage I of the GWAS. The 95% CI and P
value for the UMVCUE OR were calculated using the variance from 1,000,000 bootstrap
samples. The 9q31.2-rs865686 SNP in stage I of the discovery GWAS had P = 2.28 × 10–4,
whereas all other SNPs from the GWAS had P > 5 × 10–4 (11), hence the latter was taken as
the P value threshold within the UMVCUE calculations. We assumed that a lack of
detectable selection bias in the primary SNP association with breast cancer would justify
combining the discovery and replication sets in the secondary analyses.
Between-study heterogeneity in ORs was assessed using the Breslow–Day test. Pooled
results were adjusted for study using Cochran–Mantel–Haenszel tests. Dominant and
recessive models were also considered and departure from log-additivity was tested.
Heterogeneity in ORs between different ethnic groups was assessed by a Wald test of the
coefficients of the ethnicity covariates obtained from a logistic regression including
interactions between OR and ethnicity.
Per-allele ORs specific to each breast cancer subtype (as defined by ER, PR, and HER2
status) were estimated by taking all available controls as each reference outcome and
adjusting for study. Heterogeneity in the OR by subtypes was tested using case-only logistic
regression, with each binary receptor status as the predictor, allele (major/minor) as the
response, and study as a covariate. This model was then extended to include all receptor
statuses in a combined analysis of association and heterogeneity.
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Heterogeneity in the OR by age at diagnosis (<40, 40–49, 50–59, 60–69, 70 years) was
evaluated by conducting 5 separate case–control analyses among Europeans, taking all the
controls as the reference outcome for each subgroup, with adjustment for study. In addition,
a case-only allelic logistic regression, adjusted for study, was used to test for a linear trend
between number of copies of the G-allele and age at diagnosis.
In some studies, cases had been selected to have an increased genetic susceptibility to
improve power. To assess whether there was heterogeneity in the OR by level of genetic
enrichment of the cases, the combined OR estimate for the 10 European studies (BBCS,
CNIO-BCS, GC-HBOC, GC-HBOC, HEBCS, KARBAC, kConFab/AOCS, MBCSG, NC-
BCFR, OFBCR, and RBCS) that selected all, or a subset, of cases with increased genetic
susceptibility (e.g., those with 2 independent primaries and/or with at least one affected first-
degree relative) was compared with the combined OR estimate for the remaining 26
European studies of unselected cases, with adjustment for study within each group.
In addition, a quantitative “family history” score was assigned to each individual woman
reflecting her number of affected first-degree relatives and whether she was a unilateral or a
bilateral/ipsilateral case (a value of 2 was added to the score for bilateral/ipsilateral cases)
and included as a covariate within a logistic regression model, adjusting for study. A
significant interaction between this score and the SNP effect provided a test of effect
modification by family history.
To assess whether rs865686 is associated with age at menarche, independently of disease
status, we used linear regression with age at menarche as response and genotype as
predictor, with covariate adjustment for both case–control status and study.
All statistical tests were 2-sided. All analyses were carried out using PLINK (17, 18) and R
(19).
Results
A total of 48,394 breast cancer cases and 50,836 controls from 37 BCAC case–control
studies contributed to the analysis. Overall, 98% of the subjects were of self-reported
European ancestry and 2% were of self-reported Asian ancestry. The mean (±SD) age at
diagnosis for European cases was 55 (±14) years. The estimated minor (G)-allele frequency
(MAF) of rs865686 was significantly higher among European (MAF = 0.38) than Asian
controls (MAF = 0.09; P = 1.11 × 10–114). There was no clear evidence of subethnic
differences in the estimated MAF among Asians [0.12 for controls from the Indian
subcontinent (N = 99); 0.09 for controls from South East Asia (N = 660); P = 0.21] but,
among Europeans, the estimated MAF was lower among controls from Eastern European
populations (MAF = 0.30) than among those from other European populations (MAF = 0.38,
P = 1.08 × 10–31).
The replication set (comprising Europeans from all studies except BBCS and UKBGS)
provided strong independent support for an association between rs865686 and overall breast
cancer risk among women of European ancestry (Fig. 1), with an estimated OR of 0.90
(95% CI, 0.88–0.92; P = 1.23 × 10–25) per G-allele and no evidence of between-study
heterogeneity (Phet = 0.23). Genotype-specific ORs were 0.89 (95% CI, 0.87–0.92) for GT
vs. TT and 0.81 (95% CI, 0.78–0.85) for GG vs. TT. None of the estimates departed from
those expected under a log-additive model (P = 0.34) with the OR being 0.87 (95% CI 0.85,
0.90) and 0.87 (95% CI 0.83, 0.90), respectively, for dominant (GG and GT vs. TT) and
recessive (GG vs. GT and TT) models.
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There was no evidence of heterogeneity in the per-allele OR between the discovery and the
replication sets (Phet = 0.16; Fig. 1), with their combined data yielding a pooled per-allele
OR of 0.90 (95% CI, 0.88–0.91; P = 2.01 × 10–29) for women of European descent. This
pooled estimate is potentially biased by the “winner's curse” effect, but in fact is almost
identical to the unbiased UMVCUE estimator of Bowden and Dudbridge (ref. 16; OR
0.8999, 95% CI, 0.8823–0.9178; P = 1.07 × 10–25) and the replication estimate (OR, 0.8996;
95% CI, 0.8819–0.9176; P = 1.23 × 10–25). Therefore, any selection bias in the discovery set
is minimal, and in the following analyses, we combined the data from all women of
European ancestry.
There was no evidence of ethnic variation in the per-allele OR estimate (Phet = 0.43), but the
power of the study to detect this was low due to the relatively small sample size (N = 1,882;
1,123 cases and 759 controls) and the low MAF (0.09) among Asians. The per-allele OR
estimates were similar for non-Eastern Europeans (OR, 0.90; 95% CI, 0.88–0.91) and
Eastern Europeans (OR, 0.92; 95% CI, 0.84–1.0), and the higher estimate for Asians had a
wide CI (OR, 1.02; 95% CI, 0.80–1.31), which overlapped the other 2 CIs.
Among women of European ancestry, the allelic ORs were similar for invasive and in situ
tumors (Phet = 0.62), but differed according to receptor status (Fig. 2). The SNP was more
strongly associated with ER-positive (ER+) than ER-negative (ER–) tumors (Phet = 1.16 ×
10–6) and with PR-positive (PR+) than PR-negative (PR–) tumors (Phet = 5.14 × 10–5). There
was no evidence, albeit based on a smaller sample size, of effect modification by HER2
status (Phet = 0.64). Stratification according to the 4 different possible combinations of ER/
PR status (Fig. 2) showed that the rs865686 was strongly associated with ER+/PR+ and ER+/
PR– disease (P = 5.78 × 10–20 and P = 8.21 × 10–5, respectively) but not with ER–/PR+ or
ER–/PR– disease (P = 0.08 and P = 0.94, respectively, Phet = 1.75 × 10–7). When both ER
and PR status were modeled jointly in a case-only analysis, only the association with ER
status remained significant (P = 0.0012 for ER, P = 0.21 for PR), with no evidence of
interaction between ER and PR status (Phet = 0.27). Together, these findings are consistent
with the SNP being strongly associated with ER+ disease (per-allele OR, 0.89; 95% CI,
0.86–0.91; P = 3.13 × 10–22) but less strongly, if at all, with ER– disease (OR, 0.98; 95% CI,
0.94–1.02; P = 0.26; Fig. 2). There was no evidence of heterogeneity in ORs by tumor
histology, or receptor status, among women of Asian descent, but these analyses were based
on a much smaller sample size than for women of European ancestry (data not shown).
In women of European ancestry, case–control analyses suggest a positive trend in the
magnitude of the per-allele OR (i.e., ORs became closer to unity) with increasing age at
diagnosis of breast cancer (Table 1). This result was confirmed by a case-only analysis, but
only for ER+ tumors, which showed a significant trend (P = 0.0095) in the number of copies
of the G-allele with increasing age of onset of ER+ disease (Table 1), but did not detect any
association among either all cases, or ER– cases (P = 0.37 and P = 0.35, respectively). Note
that the estimated OR for cases diagnosed at age <40 years, albeit based on a small sample
size, did not follow the overall trend with its magnitude being as high as the OR for the
oldest age group (≥70 years). This may be due to chance or a truly different effect among
very young cases.
There was no evidence among Europeans that the per-allele OR differed (Phet = 0.97)
between the 10 case–control studies based on “genetically enriched” cases (combined per-
allele OR, 0.90; 95% CI, 0.86–0.94; P = 1.48 × 10–6) and the 26 studies based on unselected
cases (combined per-allele OR 0.90, 95% CI 0.88, 0.92, P = 2.38 × 10–24). Analyses by
family history score, which reflects number of affected first-degree relatives and whether the
woman had one (unilateral case) or 2 (ipsilateral and bilateral cases) independent primary
tumors (see Methods section), gave similar results with no evidence that the SNP-associated
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effect was modified by this variable (Phet = 0.47). The OR for bilateral disease may be
somewhat weaker than expected (20), but redefining the family history score as simply the
number of affected relatives, regardless of whether the woman was a unilateral or a bilateral/
ipsilateral case, did not affect the findings (Phet = 0.45).
Two recent GWAS (21, 22) reported associations between 9q31.2 SNPs (rs7861820,
rs12684013, rs4452860, rs7028916, and rs2090409) and age at menarche, a factor known to
affect breast cancer risk. These loci map of more than 2 Mb from rs865686 are not
correlated with it (r2 < 0.01, D′ <0.09 in CEU HapMap phase 2). We found no evidence that
rs865686 was associated with age at menarche (per-allele difference in age at menarche:
0.0017 years; 95% CI, –0.0169–0.0203; P = 0.86), within the BCAC subset of 58,983
European women (31,522 cases and 27,461 controls) with information available on age at
menarche and rs865686 genotype.
Discussion
This combined analysis of data from a large international consortium confirms 9q31.2-
rs865686 to be a breast cancer susceptibility locus in women of European ancestry, yielding
a very precise estimate of the per-allele OR among European women (OR, 0.90; 95% CI,
0.88–0.91). Replication studies have shown that genetic susceptibility to breast cancer varies
by expression levels of ER in breast tumors, with certain variants being associated with both
ER+ and ER– disease, whereas others are more strongly associated with ER+ or triple-
negative (ER–, PR–, HER2–) disease (23). Our study is the first to show that the 9q31.2-
rs865686 is associated with ER+ breast cancer but less so, if at all, with ER– disease. These
results are not affected by the “winner's curse” bias as data on receptor status were available
only for studies in the replication set. Interestingly, a recent study of African-American
women (24) found no evidence of heterogeneity by ER status (Phet = 0.17), but with a
significant association being observed among ER– (per-allele OR, 0.87; 95% CI, 0.78–0.97)
but not ER+ disease (OR, 0.94; 95% CI, 0.86–1.03; ref. 24). However, this other study had
low power to detect differences by receptor status (n = 1520 ER+ cases, 988 ER– cases, and
2,745 controls).
Our original GWAS (11) found no evidence of an association in the per-allele ORs with
either age at menarche or age at diagnosis. The present study did not reveal any association
of rs865686 with age at menarche or age at diagnosis overall among women of European
ancestry, but it found a trend in the number of copies of the G-allele with increasing age at
diagnosis among ER+ breast cancer cases. No strong trends in risk with age at diagnosis for
the other known common breast cancer SNPs have been reported despite the fact that the
familial relative risk of breast cancer is much higher at younger ages, particularly in relatives
of young cases (25).
Our study was well-powered to identify ethnic variations in MAF, with this being much
lower among women of Asian descent (MAF = 0.09) than among those of European
ancestry (MAF = 0.38), and among the latter lower among Eastern European (MAF = 0.30)
than among other European women (MAF = 0.38). However, the magnitude of the per-allele
OR for the breast cancer association was estimated less precisely in Eastern European and
Asian women. The Asian sample was markedly under powered for detecting an association
between the SNP and breast cancer risk (only 15% power at P < 0.05 as estimated by the
Genetic Power Calculator (ref. 26) assuming the same OR as estimated in European
women). Assuming a similar case–control ratio as in the present BCAC dataset in
approximately 11,000 Asian cases would be required to attain 80% power. The Eastern
European sample had a greater power (~70%), with approximately 1,000 additional cases
required to attain 80% power. Overall, these ethnic differences are consistent with those
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from the study of African-American women mentioned above (24) showing that they had a
higher MAF (0.48) than European women but a similar per-allele OR (0.93; 95% CI, 0.85–
0.99; P = 0.034).
Further genetic and functional studies will be required to identify the causal variant (or
variants) and the mechanisms underlying the 9q31.2-rs865686 association with breast cancer
risk. This SNP maps to a 17 kb region of LD (109927817-109944558 bp) on 9q31.2 with no
known genes. The nearest genes are Kruppel-like factor 4 (KLF4, 636 kb centromeric),
RAD23B (799 kb centromeric), and actin-like 7A (ACTL7A, 736 kb telomeric).
Interrogation of the Oncomine database (27) showed a decrease in KLF4 gene transcripts in
breast cancers and a correlation between KLF4 expression and ERα positivity. However, a
causal link remains to be established between these functional mechanisms and sequence
variation at or near rs865686. To motivate such functional studies, indisputable
epidemiologic evidence is needed for association between rs865686 and breast cancer,
which we now report in this study. With such evidence in place, this region now presents a
strong example of a noncoding SNP whose causal mechanism on disease is unclear.
Determination of the mechanism is a considerable challenge but will eventually shed further
light on breast cancer oncogenesis and, potentially, noncoding mechanisms in other complex
diseases.
In conclusion, this large replication study found strong evidence for an association between
the 9q31.2-rs865686 SNP and ER+ breast cancer among women of European ancestry. The
findings are consistent with breast cancer being a biologically heterogeneous disease and
highlight the need for subtype-specific studies to be conducted in different ethnic
populations.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
Forest plot of the association of 9q31.2-rs865686 with breast cancer risk among women of
European ancestry in the original GWAS, all stages combined (11), and replication within
the Breast Cancer Association Consortium (BCAC). Ca, no. cases; Co, no. controls; MAF,
minor allele frequency. Study abbreviations as in Supplementary Table S1. * The discovery
set (see Results) comprises data from 2 BCAC studies that had contributed data to the
GWAS analysis [BBCS contributed data on 1,711 (out of the 1,978 subjects examined here)
to stages 1 and 2 of the GWAS; UKBGS contributed data on 4,621 (out of the 4,661 subjects
examined here) to stage 3 of the GWAS].
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Figure 2.
9q31.2-rs865686 and breast cancer risk amongst women of European ancestry stratifying by
ER, PR, and HER2 receptor status*. Ca, no. cases; Co, no. controls; * P for heterogeneity
(Phet) in the OR by ER status: 6.9 × 10–4 amongst PR– tumors and 0.52 amongst PR+
tumors. Phet in the OR by PR status: 0.13 amongst ER– cases and 0.52 amongst ER+ cases.
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Table 1
Association of 9q31.2-rs865686 and breast cancer risk among women of European ancestry, by ER status of
the tumor and age at diagnosis
Class Age at diagnosis Cases Controls OR (95% CI)* P
All cases
Case-control analysis:
1 <40 4,934 50,216 0.93 (0.89, 0.97) 0.001
2 40–49 10,643 50,216 0.88 (0.85, 0.91) 4.21 × 10–15
3 50–59 14,703 50,216 0.88 (0.86, 0.91) 3.59 × 10–18
4 60–69 11,298 50,216 0.91 (0.88, 0.94) 5.44 × 10–10
5 ≥70 4,978 50,216 0.93 (0.89, 0.97) 0.001
NK 836 – – –
Case-only analysis:
All Exact Age 46,556 – – P for linear trend = 0.37
ER-positive cases
Case-control analysis:
<40 1,749 43,706 0.93 (0.87, 1.01) 0.066
40—49 4,593 43,706 0.84 (0.80, 0.88) 7.84 × 10–13
50—59 7,160 43,706 0.87 (0.83, 0.90) 4.53 × 10–13
60–69 6,335 43,706 0.91 (0.87, 0.95) 4.07 × 10–6
≥70 3,255 43,706 0.93 (0.88, 0.98) 0.011
NK 29
Case-only analysis:
All Exact Age 23,112 – – P for linear trend = 0.0095
ER-negative cases
Case-control analysis:
<40 1,017 43,706 0.99 (0.90, 1.09) 0.81
40-49 1,443 43,706 0.96 (0.88, 1.04) 0.28
50-59 1,923 43,706 0.98 (0.91, 1.05) 0.52
60-69 1,278 43,706 1.02 (0.94, 1.10) 0.71
≥70 567 43,706 0.95 (0.84, 1.07) 0.40
NK 9 – – –
Case-only analysis:
All Exact Age 6,228 – – P for linear trend = 0.35
Abbreviation: NK, not known.
*Study-adjusted OR and 95% CI.
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